- Home
- BOLD vs CING Comparison
BOLD vs CING Comparison
Compare BOLD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- CING
- Stock Information
- Founded
- BOLD 2018
- CING 2012
- Country
- BOLD United States
- CING United States
- Employees
- BOLD N/A
- CING N/A
- Industry
- BOLD
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- CING Health Care
- Exchange
- BOLD Nasdaq
- CING Nasdaq
- Market Cap
- BOLD 24.4M
- CING 26.7M
- IPO Year
- BOLD 2024
- CING 2021
- Fundamental
- Price
- BOLD $1.15
- CING $3.95
- Analyst Decision
- BOLD Buy
- CING Strong Buy
- Analyst Count
- BOLD 4
- CING 4
- Target Price
- BOLD $4.00
- CING $31.00
- AVG Volume (30 Days)
- BOLD 79.9K
- CING 122.5K
- Earning Date
- BOLD 11-06-2025
- CING 11-06-2025
- Dividend Yield
- BOLD N/A
- CING N/A
- EPS Growth
- BOLD N/A
- CING N/A
- EPS
- BOLD N/A
- CING N/A
- Revenue
- BOLD N/A
- CING N/A
- Revenue This Year
- BOLD N/A
- CING N/A
- Revenue Next Year
- BOLD N/A
- CING N/A
- P/E Ratio
- BOLD N/A
- CING N/A
- Revenue Growth
- BOLD N/A
- CING N/A
- 52 Week Low
- BOLD $1.00
- CING $3.02
- 52 Week High
- BOLD $4.72
- CING $6.70
- Technical
- Relative Strength Index (RSI)
- BOLD 49.88
- CING 46.19
- Support Level
- BOLD $1.13
- CING $3.70
- Resistance Level
- BOLD $1.16
- CING $4.12
- Average True Range (ATR)
- BOLD 0.04
- CING 0.24
- MACD
- BOLD 0.00
- CING 0.03
- Stochastic Oscillator
- BOLD 62.50
- CING 41.82
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.